| 生物活性 |
Isobavachin is a prenylated flavonoid found in Psoralea corylifolia that possesses oral activity and blood-brain barrier penetration, inhibits human CYP2B6, CYP2C9, CYP2C19, UGT1A1, UGT1A9, and UGT2B7, suppresses MAPK activation, NF-κB nuclear translocation, iNOS/COX-2 overexpression, FcεRI-mediated signaling pathways, and RANKL-induced osteoclastogenesis, induces autophagy, cytotoxicity, neuronal differentiation, and NRF2 activation, attenuates oxidative damage, inflammatory responses, apoptosis, iron accumulation, mitochondrial biogenesis, and mast cell degranulation, and can be used in research related to liver injury, inflammatory diseases, osteoporosis, liver cancer, prostate cancer, glioma, periodontitis-induced bone loss, and Alzheimer's disease. |
体外研究 (In Vitro) |
Isobavachin (100 nmol/L; from EB stage day 4 to day 8+10) 可通过涉及蛋白异戊二烯化、ERK 磷酸化激活以及 p38 和 JNK 磷酸化下调的机制,促进小鼠胚胎干细胞 (D3 系) 向神经元和星形胶质细胞分化。 Isobavachin (5-80 μM; 24 h) 对 AML12、HepG2、LO2 细胞,以及大鼠原代肝细胞、小鼠原代肝细胞呈剂量依赖性细胞毒性,其 IC50 值分别为 35.20 μM、19.96 μM、20.74 μM、55.84 μM 和 56.84 μM,且自噬抑制可减弱该细胞毒性。 Isobavachin (5-80 μM; 24 h) 可在 AML12、HepG2、LO2 细胞,以及大鼠原代肝细胞和小鼠原代肝细胞中诱导呈剂量依赖性的 LDH 泄漏。 Isobavachin (20-44 μM; 24 h) 可诱导 AML12 细胞中自噬体、自溶酶体和自噬空泡的数量呈剂量依赖性增加,自噬通量增强,导致线粒体进行性损伤,并降低细胞内 ATP 水平。所有这些经 MDC 荧光验证的促自噬作用均可被 AMPK 抑制剂 BAY-3827 (MS-P37527) 减弱。 Isobavachin (20-44 μM; 24 h) 可通过激活 AMPK-ULK1 通路、抑制 PI3K-Akt-mTOR 通路上调 AML12 细胞中的自噬水平,这可由自噬相关蛋白及信号通路蛋白的表达变化得到证明;而自噬抑制或 AMPK 抑制可逆转上述效应。 Isobavachin (ISO) 可高亲和力结合纯化的 PI3K 和 AKT 蛋白,结合能分别为 -8.6 kcal/mol 和 -6.4 kcal/mol。 Isobavachin (IBC) (3.75-30 μM; 3 h pre-incubation, followed by 21 h LPS treatment) 可通过抑制 MAPK 和 NF-κB 信号通路,抑制脂多糖诱导的 RAW264.7 小鼠巨噬细胞炎症反应。 Isobavachin (孵育 60 分钟) 在人肝/鼠肝/肠微粒体以及重组 CYP1A2/CYP2C19 和 UGT 同工酶中通过单氧化和葡萄糖醛酸化代谢。氧化生成代谢物 M1-M3(CLint:5.53-93.97 μl/min/mg),而葡萄糖醛酸化生成 G1-G2 (CLint:10.73-202.62 μl/min/mg),表明葡萄糖醛酸化效率更高。 Isobavachin (1-100 μM; 60 min) 可强效抑制重组人源 CYP2B6 (Ki = 1.93 μM)、CYP2C9 (Ki = 0.22 μM) 和 CYP2C19 (Ki = 1.55 μM),具有剂量依赖性的亚型特异性抑制模式。 Isobavachin (1-100 μM; 60 min) 可强效抑制重组人 UGT1A1 (Ki = 3.05 μM)、UGT1A9 (Ki = 0.44 μM) 和 UGT2B7 (Ki = 0.05 μM),具有剂量依赖性的同工酶特异性抑制模式。 Isobavachin (10 μM; 60 min) 在人单个肝微粒体中的单氧化反应与葡萄糖醛酸化反应,与 CYP1A2、CYP2C19、UGT1A1 及 UGT1A9 的活性显著相关。 Isobavachin (Iso) (1-10 μM; 1 h pre-incubation, 5-15 min Ag stimulation) 可浓度依赖性地抑制骨髓来源肥大细胞中由 IgE/Ag 刺激引发的脱颗粒、类花生酸生成以及细胞内 Ca2+ 升高。 Isobavachin (1.3-5 μM) 浓度依赖性地抑制肥大细胞中 IgE/Ag 诱导的炎症基因,以及 RAW 264.7 和腹腔巨噬细胞中 LPS 触发的 NO、相关转录物和 NF-κB 活化。 Isobavachin (10 μM; 1 h pre-incubation, 15 min Ag stimulation) 可抑制骨髓来源肥大细胞中由 IgE/Ag 激活的近端酪氨酸激酶 (Fyn、Lyn、Syk、Lck) 及其包括 NF-κB 在内的下游信号通路的活化。 Isobavachin (10 μM; 5 min-4 h incubation) 以 Fyn 和 Lyn 依赖的方式上调静息状态骨髓来源肥大细胞中 SHP-1 的磷酸化水平。 Isobavachin (10 μM; 转染 SHP-1 siRNA 48 小时后,先预孵育 1 h,再用 Ag 刺激 5 min-4 h) 对 IgE/Ag 激活的骨髓来源肥大细胞的活化与信号通路具有抑制作用,且该作用依赖于 SHP-1。 Isobavachin (7.5-30 μM; days 1-3, days 3-5, days 5-7) 可以剂量和时间依赖的方式抑制 RANKL 诱导的骨髓来源巨噬细胞破骨细胞生成,其 IC50 为 15 μM,且主要在分化的早期至中期发挥作用。 Isobavachin (15-30 μM; 96 h) 可下调 RANKL 刺激的骨髓来源巨噬细胞中破骨细胞关键标记基因和蛋白的表达。 Isobavachin (15-30 μM; 5 days) 可在体外以剂量依赖的方式抑制 RANKL 诱导的骨髓来源巨噬细胞中 F-actin 环的形成。 Isobavachin (15-30 μM; 7 days) 可呈剂量依赖性抑制破骨细胞介导的骨吸收以及骨切片上的 F-肌动蛋白环形成。 Isobavachin 可改变 RANKL 诱导破骨细胞的转录组,与铁离子稳态、ROS 代谢及 MAPK 信号通路相关的基因显著富集。 Isobavachin (15-30 μM; 48-96 h) 可通过上调 Fpn1 表达、下调 Tfr1、Ftl1 和 Fth1 表达以促进铁外流,从而减少 RANKL 诱导的破骨细胞 (骨髓来源巨噬细胞及 RAW264.7 细胞) 中的细胞内铁蓄积。 Isobavachin (30 μM; 5 days) 可通过上调 Fpn1 表达抑制 RAW264.7 细胞中 RANKL 诱导的破骨细胞生成,Fpn1 敲低可部分逆转其作用、Fpn1 过表达可增强其作用的实验结果证明了这一点。 Isobavachin (30 μM; 0, 15, 30, 60 min) 可通过抑制 MAPK 信号通路 (P38、JNK 及 ERK) 上调 RANKL 刺激的 RAW264.7 细胞中 Fpn1 的表达。 Isobavachin (30 μM; 96 h) 可抑制 RANKL 诱导的骨髓来源巨噬细胞的线粒体生物发生与功能,表现为线粒体基因表达、线粒体质量、线粒体 DNA 拷贝数、膜电位、ROS 生成及 ATP 水平降低。 Isobavachin 可强效且选择性地结合人重组 ApoE4 (Kd = 0.54 μM) 和人重组 ApoE3 (Kd = 0.62 μM)。 Isobavachin (IBA) (7.5-30 μM) 以剂量和时间依赖的方式抑制 RANKL 诱导的骨髓单核细胞 (BMM) 破骨细胞生成 (IC50 = 15 μM),主要作用于早期至中期分化阶段,并且在 5 天处理后也能抑制 RAW264.7 细胞的破骨细胞形成。 Isobavachin (15-30 μM) 在 RANKL 刺激的骨髓单核细胞 (BMM) 中孵育 96 小时后,可抑制破骨细胞标志物的 mRNA 和蛋白水平,下调铁摄取/储存基因和蛋白,同时上调铁外排 FPN1。此外,它还能减少 BMM 和 RAW264.7 细胞中的总铁和亚铁积累。另外,它还能剂量依赖性地抑制 BMM 中 F-肌动蛋白环的形成 (5 天) 和破骨细胞介导的骨吸收 (7 天)。 Isobavachin (30 μM) 抑制 RAW264.7 细胞中 RANKL 诱导的 p38、JNK 和 ERK MAPK 通路的激活,从而上调了 FPN1。它对 RANKL 触发的破骨细胞生成的抑制作用部分是通过 FPN1 上调介导的,并且通过 FPN1 过表达进一步增强。
Cell Differentiation Assay
| Cell Line: |
mouse embryonic stem (D3 line) cells |
| Concentration: |
100 nmol/L |
| Incubation Time: |
from EB stage day 4 to day 8+10 |
| Result: |
Elevated nestin expression in EBs at day 4 and day 8+0. Time-dependently upregulated neuronal β-tubulin III, astrocytic GFAP and axonal NEFM at day 8+5 and day 8+10, and increased neuron-like cell populations by day 8+10 relative to solvent control. Suppressed p38 and JNK phosphorylation, while enhanced ERK phosphorylation during late neuronal differentiation. GGTI-298 co-treatment abrogated the promotive effects on neurons and astrocytes. |
Cell Viability Assay
| Cell Line: |
HepG2, LO2, AML12, rat primary hepatocytes, mouse primary hepatocytes |
| Concentration: |
5, 10, 20, 30, 40, 50, 60, 70, 80 μM (AML12 cells) 0.625, 1.25, 2.5, 5, 10, 20, 40, 80 μM (HepG2 cells, LO2 cells) 30, 40, 50, 60, 70, 80 μM (Rat primary hepatocytes) 8, 16, 24, 32, 4, 48, 56, 64 μM (mouse primary hepatocytes) |
| Incubation Time: |
24 h |
| Result: |
Exerted dose-dependent cytotoxicity in AML12, HepG2, LO2, rat primary hepatocytes, and mouse primary hepatocytes with IC50 values of 35.20 μM, 19.96 μM, 20.74 μM, 55.84 μM, and 56.84 μM, respectively, and autophagy inhibition attenuates this cytotoxicity. |
Cell Autophagy Assay
| Cell Line: |
AML12 cells |
| Concentration: |
20, 32, 44 μM (general); 32 μM (BAY-3827 (MS-P37527) co-treatment) |
| Incubation Time: |
24 h (isobavachin treatment); 30 min (MDC staining incubation) |
| Result: |
Elevated MDC fluorescence intensity in a dose-dependent manner, rising by 223.12% at 32 μM and 353.82% at 44 μM relative to the control. BAY-3827 pretreatment decreased the fluorescence intensity by 48.67% compared with the isobavachin-only group. |
Cell Autophagy Assay
| Cell Line: |
AML12 cells |
| Concentration: |
20, 32, 44 μM (general); 32 μM (BAY-3827 co-treatment) |
| Incubation Time: |
24 h (Ad-mCherry-GFP-LC3B transfection); 24 h (isobavachin treatment) |
| Result: |
Altered GFP and mCherry fluorescence in a dose-dependent manner to reflect elevated autophagic flux. BAY-3827 pretreatment reversed such fluorescence changes and suppressed autophagic flux. |
Western Blot Analysis
| Cell Line: |
AML12 cells |
| Concentration: |
20, 32, 44 μM (general); 32 μM (3-MA (MS-H80278) or BAY-3827 co-treatment) |
| Incubation Time: |
24 h (isobavachin treatment); overnight (primary antibody incubation) |
| Result: |
Caused dose-dependent increases in LC3II/I, Atg5, and Beclin-1 protein levels, and dose-dependent decreases in p62 protein levels. Increased p-AMPK and p-ULK1 levels, and decreased p-PI3K, p-Akt, and p-mTOR levels. Reversed isobavachin-induced changes after pretreatment with 3-MA: p62 levels increased, LC3II/I levels decreased, p-PI3K, p-Akt, and p-mTOR levels increased, and p-ULK1 levels decreased. Reversed isobavachin-induced changes after pretreatment with BAY-3827: p62 levels increased, LC3II/I levels decreased, p-AMPK and p-ULK1 levels decreased, and p-mTOR levels increased. |
RT-PCR
| Cell Line: |
murine macrophage RAW264.7 cells |
| Concentration: |
3.75, 7.5, 15, 30 μM |
| Incubation Time: |
3 h pre-incubation, followed by 21 h LPS treatment |
| Result: |
Downregulated LPS-induced iNOS and COX-2 mRNA and protein expression in a dose-dependent manner. Suppressed LPS-induced secretion of TNF-α, IL-6, and IL-1β respectively, at 30 μM. |
Western Blot Analysis
| Cell Line: |
murine macrophage RAW264.7 cells |
| Concentration: |
3.75, 7.5, 15, 30 μM |
| Incubation Time: |
3 h pre-incubation, followed by 21 h LPS treatment |
| Result: |
Reduced LPS-induced NO and PGE2 production in a dose-dependent manner. Inhibited LPS-induced phosphorylation of ERK, JNK, and p38 MAPK; reduced ERK, JNK, and p38 phosphorylation by 66.5%, 50.2%, and 67.8%, respectively, at 30 μM. Inhibited LPS-induced phosphorylation and degradation of IκBα, and blocks NF-κB p65 translocation from the cytoplasm to the nucleus. |
RT-PCR
| Cell Line: |
bone marrow-derived mast cells (BMMCs) |
| Concentration: |
1.3, 2.5, 5 μM |
| Incubation Time: |
1 h pre-incubation; 4 h Ag stimulation post-pre-incubation |
| Result: |
Reduced IgE/Ag-induced mRNA expression of TNF-α and IL-6 in a concentration-dependent manner. |
Western Blot Analysis
| Cell Line: |
bone marrow-derived mast cells (BMMCs) |
| Concentration: |
10 μM |
| Incubation Time: |
1 h pre-incubation; 15 min Ag stimulation post-pre-incubation |
| Result: |
Suppressed IgE/Ag-stimulated tyrosine phosphorylation of Fyn, Lyn, Syk, Lck, and LAT. Reduced phosphorylation of active Lck (Y394) and downstream signaling molecules PLCγ1, AKT, p38, ERK1/2, and JNK. Reduced IgE/Ag-stimulated phosphorylation of IKK and NF-κB p65. Inhibited nuclear translocation of NF-κB p65. |
Western Blot Analysis
| Cell Line: |
bone marrow-derived mast cells (BMMCs) |
| Concentration: |
10 μM |
| Incubation Time: | ...(内容过长已截断)
体内研究 (In Vivo) |
Isobavachin (ISO) (10 mg/kg;口服) 可对小鼠中对 Acetaminophen (MS-H20928) 诱导的肝损伤发挥显著的肝保护作用,,主要通过抑制 CYP2E1 介导的对 Acetaminophen 的生物活化、激活 NRF2 抗氧化通路及激活 PI3K/AKT 抗凋亡信号级联反应。 Isobavachin (IBC) (1-10 μM;浸泡;LPS 刺激前预处理 3 小时) 可强效抑制斑马鱼胚胎中 LPS 诱导的炎症反应 (NO、ROS、中性粒细胞水平),且在此剂量下不会降低胚胎存活率。 Isobavachin (40 mg/kg;口服;单次给药) 在健康雄性 KM 小鼠体内发生广泛的体内代谢,生成 2 种葡萄糖醛酸结合物和 3 种单氧化代谢物,其中葡萄糖醛酸化是主要代谢途径。 Isobavachin (Iso) (10-20 mg/kg,灌胃,单剂量,过敏原激发前 1 小时) 可剂量依赖性地减轻小鼠体内肥大细胞介导的被动皮肤过敏反应,其中 20 mg/kg 剂量的效力与 50 mg/kg fexofenadine (MS-P89327) 相当。 Isobavachin (30 mg/kg;腹腔注射;每日 1 次;连续 10 天) 可通过减少破骨细胞生成缓解 C57BL/6 小鼠结扎诱导的牙周炎相关性牙槽骨丢失。 Isobavachin (30 mg/kg;腹腔注射;每日给药;连续 10 天) 可通过抑制结扎诱导的牙周炎小鼠模型中的破骨细胞生成,显著减少牙槽骨丢失,同时在骨形态计量学参数上呈现可测量的改善,并降低破骨细胞活性标志物水平。
| Animal Model: |
C57BL/6 J (male, 6 weeks old, 20-25 g, acetaminophen-induced liver injury model) |
| Dosage: |
10 mg/kg |
| Administration: |
p.o.; single dose; administered 30 min after acetaminophen exposure |
| Result: |
Significantly lowered serum ALT and AST, and restored liver color and morphology against acetaminophen-induced injury. Mitigated hepatic necrosis, hydropic degeneration and inflammation, decreased TUNEL-positive hepatocytes, and normalized Ki67 expression as well as liver-to-body weight ratio. Reduced TNF-α and IL-1β at protein and mRNA levels, relieved oxidative stress by decreasing MDA and recovering T-SOD and CAT activities. Modulated the NRF2/KEAP1 pathway, downregulated CYP2E1 and APAP-CYS adducts, and activated PI3K/AKT signaling with elevated BCL2 expression. |
| Animal Model: |
Tg(mpx:eGFP) (7 hpf embryos; inflammation model via LPS challenge) |
| Dosage: |
1 μM, 5 μM, 10 μM |
| Administration: |
immersion; pre-treatment for 3 hours prior to LPS stimulation |
| Result: |
Significantly suppressed LPS-induced NO production, ROS production, and neutrophil counts.
|
| Animal Model: |
KM mice (male, SPF grade, 6-8-week-old) |
| Dosage: |
40 mg/kg |
| Administration: |
p.o.; single dose |
| Result: |
Identified five metabolites of isobavachin in mouse serum, bile, urine, faeces, and liver: two glucuronides (G1: isobavachin-7-O-glucuronide; G2: isobavachin-4'-O-glucuronide) and three mono-oxidated products (M1, oxidized at the isopentenyl group; M2, oxidized at the B ring; M3, oxidized at the A ring). Detected glucuronide metabolites as more abundant than mono-oxidated products across all collected biosamples. |
| Animal Model: |
ICR (male, 7 weeks old) |
| Dosage: |
10 mg/kg; 20 mg/kg |
| Administration: |
p.o.; single dose; 1 h before Ag challenge |
| Result: |
Significantly reduced IgE/Ag-induced Evans blue dye extravasation and serum levels of leukotriene C4 (LTC4) and prostaglandin D2 (PGD2) compared to IgE/Ag alone. Produced a greater, dose-dependent reduction in dye extravasation and serum LTC4 and PGD2 levels, with inhibitory potency comparable to 50 mg/kg fexofenadine (MS-P89327). |
| Animal Model: |
C57BL/6 (male, 7-8 weeks old, 22-24 g, ligature-induced periodontitis) |
| Dosage: |
30 mg/kg |
| Administration: |
i.p.; once daily; 10 days |
| Result: |
Reduced CEJ-ABC distance from ~0.5 mm to ~0.35 mm. Elevated BV/TV (5% to 15%) and Tb.N (0.7 /mm to 1.3 /mm), while lowered Tb.Sp (0.35 mm to 0.28 mm). Decreased N.Oc/BS (11 /mm to 5 /mm) and Oc.S/BS (17% to 12%), and attenuated CTSK fluorescence intensity (100 to 60). Enhanced fluorescence intensity of iron exporter FPN1 (100 to 130). |
| Animal Model: |
C57BL/6 (male, 7-8 weeks old, 22-24 g, ligature-induced periodontitis model) |
| Dosage: |
30 mg/kg |
| Administration: |
i.p.; daily; 10 days |
| Result: |
Reduced CEJ-ABC distance from ~0.5 mm to ~0.35 mm. Raised BV/TV from ~5% to ~15% and Tb.N from ~0.7 /mm to ~1.3 /mm, and decreased Tb.Sp from ~0.35 mm to ~0.28 mm. Lowered N.Oc/BS (~11 /mm to ~5 /mm) and Oc.S/BS (~17% to ~12%), and reduced CTSK fluorescence intensity from ~100 to ~60. Elevated FPN1 fluorescence intensity from ~100 to ~130. |
|
| 性状 |
固体 |
| 颜色 |
White to light yellow |
| 分子量 |
324.37 |
| 分子式 |
C20H20O4 |
| CAS No. |
31524-62-6 |
| 别名 |
异补骨脂二氢黄酮 |
| 体内实验配方 |
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (6.17 mM), Sonication is recommended. 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 |
| 储存方式 |
4°C, protect from light
|
| 运输条件 |
Room temperature in continental US; may vary elsewhere. |
|
溶液配制表
|
DMSO 中的溶解度 : 100 mg/mL (308.29 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO) | 可选溶剂 | 浓度 | 1 mg | 5 mg | 10 mg | 25 mg |
|---|
| DMSO | 1 mM | 3.0829 mL | 15.4145 mL | 30.8290 mL | 77.0725 mL | | 5 mM | 0.6166 mL | 3.0829 mL | 6.1658 mL | 15.4145 mL | | 10 mM | 0.3083 mL | 1.5414 mL | 3.0829 mL | 7.7072 mL | | 15 mM | 0.2055 mL | 1.0276 mL | 2.0553 mL | 5.1382 mL | | 20 mM | 0.1541 mL | 0.7707 mL | 1.5414 mL | 3.8536 mL | | 25 mM | 0.1233 mL | 0.6166 mL | 1.2332 mL | 3.0829 mL | | 30 mM | 0.1028 mL | 0.5138 mL | 1.0276 mL | 2.5691 mL | | 40 mM | 0.0771 mL | 0.3854 mL | 0.7707 mL | 1.9268 mL | | 50 mM | 0.0617 mL | 0.3083 mL | 0.6166 mL | 1.5414 mL | | 60 mM | 0.0514 mL | 0.2569 mL | 0.5138 mL | 1.2845 mL | | 80 mM | 0.0385 mL | 0.1927 mL | 0.3854 mL | 0.9634 mL | | 100 mM | 0.0308 mL | 0.1541 mL | 0.3083 mL | 0.7707 mL |
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。
该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。
|
动物实验计算换算器
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。
-
客服
2851296953
18923798467
微信洽谈
|